Albireo Pharma (ALBO) 10-Q2013 Q1 Quarterly report

Filed: 14 Feb 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: algorithmically, Apidra, Australia, begun, bihormonal, BIOD, blood, capacity, check, compatible, conservative, device, earned, easier, easy, electronically, endpoint, expertise, fiduciary, filer, forecast, hierarchy, Identification, individual, infrequently, instrument, Interactive, IRS, issuer, lab, low, mark, NIH, optimized, portable, post, posted, precedent, preceding, premier, reproducibility, resubmit, Rule, shell, shorter, shown, situation, smaller, sublicensable, suited, superior, superiority, top, transparency, unrealized, volume, Washington, Web, worldwide, Yeso

Removed: adequately, allocate, anniversary, ASU, basal, bid, biosimilar, Bulletin, Carlo, charged, chemistry, clarify, compensatory, comprehensive, concept, consecutive, counted, crossover, declare, declined, decreasing, Deferral, delist, delisted, delisting, delivered, Department, director, dropping, enforcing, Enject, entity, error, exacerbate, Exanatide, facility, formal, free, fungible, goal, growing, half, implementation, India, inspection, introduced, LAR, Liraglutide, listing, localized, managed, Medicare, minimum, mm, Monte, moving, Nasdaq, NOL, oral, passed, patentable, peer, peptide, personal, pertaining, pharmacy, prandial, preparing, pressure, pro, prosecuting, prospect, published, pulmonary, qualifying, rata, reclassification, recur, reduction, remained, remediate, renegotiating, requested, requirement, reset, retirement, revaluation, SAB, saving, simulation, spray, standard, statistical, strip, therapy, title, tolerability, trading, treated, twenty, usage, visual, widespread

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ALBO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.01

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Biodel Inc. (the Company ) for the fiscal quarter ended December 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (theReport ), the undersigned Errol B. De Souza, President and Chief Executive Officer of the Company and Gerard Michel, Chief Financial Officer of the Company, each hereby certifies that: (1) the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.







Dated: February 14, 2013	/s/ Errol B. De Souza
	Errol B. De Souza, President and
	Chief Executive Officer


Dated: February 14, 2013	/s/ Gerard Michel
	Gerard Chief Financial Officer,
	VP Corporate Development, and Treasurer

-51-

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.